Chronic kidney disease (CKD) is a leading public health problem. It is understood to affect 13.4% of the world’s population, and the number of patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated at between 4.902 and 7.083 million.
How can Newcells Biotech’s aProximate™ help model CKD and identify novel therapeutics for CKD?
aProximate™ expresses the full range of relevant transporters involved in phosphate uptake – sodium-dependent phosphate transporters NaPi-IIa, NaPi-IIc, PIT2, NPT1, NPT4 and NPT5. The aProximate™ platform has been validated as a model for phosphate transport by demonstrating dose dependent inhibition of these transporters by klotho and parathyroid hormone, highlighting the relevance of this platform as an in vitro model for CKD.
aProximate™ also expresses all the relevant transporters critical for drug handling (including major transporters OAT1, OAT3, OCT2 and MATE and endocytic receptors megalin and cubilin) and allows detection of FDA qualified kidney-specific biomarkers in response to injury such as KIM-1, NGAL and Clusterin.
aProximate™ is available from humans and four preclinical species including rat, mouse, dog and non-human primate (NHP) simplifying cross species comparison and improve prediction of clinical outcomes (Bajaj et al., 2020)
Newcells Biotech also offers a high quality and reliable service for assessment of customer compounds carried out by our experienced scientists. Our service includes the design, development, and completion of study protocols in our UK laboratories, working closely with our customers with our leading kidney expert Dr Collin Brown, to define a tailored study design that best delivers the data that they require.
For further details, watch our webinar ‘Kidney as a Target: The Important Role of SLCs (Sodium Linked Co-Transporters)’.
Interested in our aProximate™ model?Contact us
Share on social media:
Don't miss out on our latest innovations: follow us on Linkedin
25th October, 2021